Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

Download

Total Articles

4
(from Reference Citation Analysis)

Article PDFs (0)

Cited by > 0 (0)

Searched Name

Soliqua

Ranked By

Results Analysis

Year Published Analysis
Article Type Analysis
Publication Title Analysis
Category Analysis

Results Analysis

Indexed Articles

Year Published

Show more Refine

Article Type

Show more Refine

Article Statistics

Refine

MESH Headings

Show more Refine

First Author

Show more Refine

First Author Affiliations

Show more Refine

Authors

Show more Refine

Publication Titles

Show more Refine

Grant Agencies

Show more Refine

Countries/Regions

Show more Refine

Affiliations

Show more Refine

Corresponding Author Affiliations

Show more Refine

Category

Show more Refine

Number	Citation Analysis
1	Drugs for type 2 diabetes. Med Lett Drugs Ther 2022;64:177-84. [PMID: 36384763] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/16/2023] Abstract Collapse Key Words Actoplus Actos Adlyxin Amaryl Bydureon Byetta Duetact Farxiga Glucotrol Glumetza Glynase Glyxambi Invokamet Invokana Janumet Januvia Jardiance Jentadueto Kazano Kombiglyze Mounjaro Nesina Onglyza Oseni Ozempic Qtern Riomet Rybelsus Saxenda Segluromet Soliqua Steglatro Steglujan Synjardy Tradjenta Trulicity Victoza Wegovy Xigduo Xultophy acarbose adverse effects alogliptin canagliflozin dapagliflozin degludec dosage drug interactions dulaglutide efficacy empagliflozin ertugliflozin exenatide glargine glimepiride glipizide glyburide insulin lactation linagliptin liraglutide lixisenatide metformin miglitol nateglinide pioglitazone pregnancy repaglinide rosiglitazone safety saxagliptin semaglutide sitagliptin tirzepatide type 2 diabetes Collapse MESH Headings Humans Diabetes Mellitus, Type 2/diagnosis Diabetes Mellitus, Type 2/drug therapy Hypoglycemic Agents/adverse effects Antipsychotic Agents Collapse Grants Collapse Affiliation(s) Collapse
2	Drugs for type 2 diabetes. Med Lett Drugs Ther 2019;61:169-78. [PMID: 31770362] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/10/2023] Abstract Collapse Key Words Actoplus Actos Adlyxin Alpha-Glucosidase Inhibitors Amaryl Avandia Bydureon Byetta Cycloset DPP-4 inhibitors DiaBeta Diamicrone Duetact Farxiga Forxiga GLP-1 receptor agonists GlucoNorm Glucobay Glucophage Glucotrol Glumetza Glynase Glyset Glyxambi Invokamet Invokana Janumet Januvia Jardiance Jentadueto Kazano Kombiglyze Komboglyze Lodalis Meglitinides Nesina Onglyza Oseni Ozempic Precose Qtern Qternmet Riomet Rybelsus SGLT2 inhibitors Segluromet Soliqua Steglatro Steglujan Sulfonylureas Symlin Synjardy TZD Thiazolidinediones Tradjenta Trajenta Trulicity Victoza Welchol Xigduo Xultophy acarbose adverse effects alogliptin alogliptin/metformin alogliptin/pioglitazone bromocriptine canagliflozin canagliflozin/metformin colesevelam dapagliflozin dapagliflozin/metformin degludec dosage dulaglutide efficacy empagliflozin ertugliflozin exenatide glargine gliclazide glimepiride glipizide glyburide insulin linagliptin linagliptin/metformin liraglutide lixisenatide metformin miglitol nateglinide pioglitazone pramlintide pregnancy repaglinide rosiglitazone safety saxagliptin saxagliptin/metformin semaglutide sitagliptin sitagliptin/metformin type 2 diabetes Collapse MESH Headings Diabetes Mellitus, Type 2/drug therapy Dipeptidyl-Peptidase IV Inhibitors/adverse effects Dipeptidyl-Peptidase IV Inhibitors/therapeutic use Drug Compounding Glucagon-Like Peptide-1 Receptor/agonists Humans Hypoglycemic Agents/adverse effects Hypoglycemic Agents/therapeutic use Insulin/adverse effects Insulin/therapeutic use Metformin/adverse effects Metformin/therapeutic use Sodium-Glucose Transporter 2 Inhibitors/adverse effects Sodium-Glucose Transporter 2 Inhibitors/therapeutic use Sulfonylurea Compounds/adverse effects Sulfonylurea Compounds/therapeutic use Thiazolidinediones/adverse effects Thiazolidinediones/therapeutic use Collapse Grants Collapse Affiliation(s) Collapse
3	Insulins for type 2 diabetes. Med Lett Drugs Ther 2019;61:65-8. [PMID: 31169803] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/09/2023] Abstract Collapse Key Words Admelog Afrezza Apidra Basaglar Basal insulins Fiasp Humalog Humulin Lantus Levemir Long-acting insulin/GLP-1 receptor agonist combinations Novolin Novolog Novorapid Prandial insulin ReliOn Soliqua Toujeo Tresiba Xultophy adverse effects degludec detemir dosage efficacy glargine insulin liraglutide lixisenatide pregnancy safety type 2 diabetes Collapse MESH Headings Diabetes Mellitus, Type 2/drug therapy Diabetes Mellitus, Type 2/physiopathology Humans Hypoglycemic Agents/administration & dosage Insulins/administration & dosage Collapse Grants Collapse Affiliation(s) Collapse
4	Expanded table: some available insulins for type 2 diabetes. Med Lett Drugs Ther 2019;61:e73-7. [PMID: 31169807] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/09/2023] Abstract Collapse Key Words Admelog Afrezza Apidra Basaglar Fiasp Humalog Humulin Lantus Levemir Novolin Novolog Novorapid ReliOn Soliqua Toujeo Tresiba Xultophy adverse effects degludec dosage efficacy glargine insulin liraglutide lixisenatide safety type 2 diabetes Collapse MESH Headings Diabetes Mellitus, Type 2/drug therapy Diabetes Mellitus, Type 2/physiopathology Humans Hypoglycemic Agents/administration & dosage Insulins/administration & dosage Collapse Grants Collapse Affiliation(s) Collapse